GlassScriptPhysician profile
Robert W Wrona
NPI 1841244043
$16,894.99
in general payments reported to CMS, 2019-2025
53 companies · $2,458 in 2025
The $2,458 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,563 · 2020: $1,993 · 2021: $2,578 · 2022: $2,520 · 2023: $2,220 · 2024: $2,562 · 2025: $2,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,240.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,096.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,676.79 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,234.68 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $1,221.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,168.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,007.71 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $975.34 | 2019-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $682.93 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $564.45 | 2021-2025 | |
| Amarin Pharma, INC. | $554.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $496.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $455.39 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $454.46 | 2019-2023 | Steglatro |
| Lundbeck LLC | $391.72 | 2022-2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $353.28 | 2023-2025 | Edarbi, Edarbi |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $341.44 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $286.82 | 2019-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $242.07 | 2024-2025 | Voquezna |
| Abbott Laboratories | $230.39 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| E.R. Squibb & Sons, L.L.C. | $226.81 | 2021-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.73 | 2019-2023 | Cycloset |
| Vanda Pharmaceuticals INC. | $214.92 | 2020-2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $201.90 | 2019-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $180.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $177.60 | 2024-2025 | Tymlos |
| Aimmune Therapeutics, INC. | $125.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $118.00 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $114.48 | 2021-2024 | Veozah |
| Corcept Therapeutics | $109.83 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $94.77 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $78.14 | 2020-2022 | |
| Watermark Medical, INC. | $50.09 | 2021 | |
| Ibsa Pharma INC. | $47.29 | 2019-2025 | Licart, Tirosint, Flector |
| Bausch Health US, LLC | $46.26 | 2021-2022 | |
| Aytu Biopharma, INC. | $40.52 | 2019-2020 | |
| Allergan, INC. | $39.07 | 2019-2020 | |
| Edwards Lifesciences Corporation | $36.29 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $35.62 | 2022-2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $35.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.26 | 2019 | |
| Dermira, INC. | $30.85 | 2020 | |
| Inspire Medical Systems, INC. | $28.43 | 2023-2024 | Inspire |
| Recordati_rare_diseases_inc. | $23.31 | 2025 | Isturisa |
| Viatris Specialty LLC | $19.44 | 2025 | Yupelri |
| Lucid Diagnostics INC. | $17.89 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.63 | 2024 | Caplyta |
| Dexcom, INC. | $16.61 | 2023 | Dexcom G6 Transmitter |
| Phadia US INC. | $15.66 | 2019 | |
| Adlon Therapeutics L.P. | $14.92 | 2020 | |
| Genentech USA, INC. | $14.82 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.97 | 2024 | Gvoke Hypopen |
| Echosens North America, INC. | $10.94 | 2025 | Fibroscan |
| Theracosbio, LLC | $9.59 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wrona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.